Keyphrases
Neuroblastoma
100%
Patient Characteristics
50%
TIGIT
50%
Aberrations
50%
Tumor Characteristics
50%
Multiorgan Donor
50%
Nectin-2
50%
Mutational Spectrum
50%
Single-cell RNA Sequencing (scRNA-seq)
50%
Integrative Analysis
50%
Breast Cancer
50%
Transplant Recipients
50%
Immunomodulatory
25%
Complete Response
25%
Exon Deletion
21%
Missense
14%
ATRX mutation
14%
B Cells
12%
Immune Checkpoint
12%
Combination Strategy
12%
Pediatric Patients
12%
Treatment Options
12%
Effective Treatment
12%
Interaction Analysis
12%
Donor Nephrectomy
12%
Tumor
12%
Programmed Death-ligand 1 (PD-L1)
12%
High-risk Neuroblastoma
12%
Syngeneic Model
12%
NKT Cells
12%
Donor Organs
12%
Immunotherapy Efficacy
12%
Immunotherapeutics
12%
Promising Target
12%
Poor Survival
12%
Post-chemotherapy
12%
Chemotherapy Resistance
12%
Survival Rate
12%
T Cells
12%
Reduced Cytotoxicity
12%
Relapse Prevention
12%
Natural Killer Cells
12%
PD-1 Blockade
12%
Transplantation
12%
Cancer Dissemination
12%
Chemotherapy
12%
Donor-derived
12%
Organ Donor
12%
Complete Remission
12%
Immunosuppression
12%
Medicine and Dentistry
Ganglioneuroblastoma
100%
Neoplasm
60%
RNA Sequence
50%
Immunotherapy
50%
Transplantation
50%
Breast Cancer
50%
Chemotherapy
30%
Programmed Death-Ligand 1
20%
Organ Donor
20%
T Cell
20%
Survival Rate
10%
Immunosuppressive Drug
10%
Natural Killer Cell
10%
Cytotoxicity
10%
B Cell
10%
Natural Killer Cell
10%
Pediatrics Patient
10%
Side Effect
10%
Disease
10%
Immunosuppressive Treatment
10%
Nephrectomy
10%
Immunity
10%
Point Mutation
6%
Helicase
6%
Solid Malignant Neoplasm
6%
Cell Line
6%
Immunology and Microbiology
Immunotherapy
50%
RNA Sequence
50%
Programmed Death-Ligand 1
33%
Immunity
16%
B Cell
16%
Immunosuppressive Drug
16%
Natural Killer T Cell
16%
T Cell
16%
Survival Rate
16%
Myeloid
16%
Syngenic
16%
Natural Killer Cell
16%
Cytotoxicity
16%
